RichardBeckerMD

PubMed

• 450 citations
  Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
  Iacopo Olivotto, Artur Oreziak, Roberto Barriales-Villa, Theodore P. Abraham, Ahmad Masri
  Lancet. 2020-09-12
• 205 citations
  A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: ...
  Christopher P. Cannon, Carolyn H. McCabe, Timothy D. Henry, Marc J. Schweiger, Robert S. Gibson
  Journal of the American College of Cardiology. 1994-04-01
• 3 citations
  Factor Xa inhibitors: critical considerations for clinical development and testing
  Richard C. Becker
  Journal of Thrombosis and Thrombolysis. 2021-05-15

Journal Articles

• Translation and Clinical Development of Antithrombotic Aptamers  
  Nimjee SM, Povsic TJ, Sullenger BA, Becker RC, Nucleic Acid Ther, 1/16/2016
• Aspirin dosing in the primary and secondary prevention of cardiovascular events  
  Kim J, Becker RC, J Thomb Thrombolysis, 1/6/2016
• The biochemistry, enzymology and pharmacology of non-vitamin K anticoagulant drug reversal agents and antidotes  
  Becker RC, J Thomb Thrombolysis, 1/1/2016
• North American Thrombosis Forum, AF Action Initiative Consensus Document  
  Ruff CT, Ansell JE, Becker RC, Benjamin EJ, Deicicchi DJ, Mark Estes NA, Ezekowitz MD, Fanikos J, Fareed J, Garcia D, Giugliano RP, Goldhaber SZ, Granger C, Healey JS,..., American Journal of Medicine, 1/1/2016
• Polypharnacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation  
  Piccini Jonathan P, Hellkamp Anne S, Washburn Jeffrey B, Becker Richard C, Breidhardt Günter, Berkowitz Scott D, Halperin Jonathan L, Hankey Graeme J, Hacke Werner, Ma..., Circulation, 1/1/2016
• Native valve disease iin patients with non-valvular atrial fibrillation on warfarin or rivaroxaban  
  Breithardt Günter, Baumgartner Helmut, Berkowitz Scott D, Helkamp Anne S, Piccini Jonathan P, Lokhnygina Yuliya, Halperin Jonathan L, Singer Daniel E, Hankey Graeme J,..., Heart, 1/1/2016
• Translation and Clinical Development of Antithrombotic Aptamers  
  Nimjee Shahid M, Provsic Thomas J, Sullenger Bruce A, Becker Richard C, Nucleic Acid Therapeutics, 1/1/2016
• Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acutecoronary sydromes: results from the PLATO study  
  Hagstrom E, James SK, Bertilsson M, Becker RC, Himmelmann A, Husted S, Katus HA, Steg PG, Storey RF, Siegbehn A, Wallentin L; PLATO Investigators, Eur Heart J, 1/28/2015
• The biochemistry, enzymology and pharmacology of non-vitamin K anticoargulant drug reversal agents and antidotes  
  Becker RC, J Thomb Thrombolysis, 1/17/2015
• Polypharmacy and the Efficacy and Safety of Rivaroxaban versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation  
  Piccini Jonathan P, Hellkamp Anna S, Washam Jeffrey B, Becker Richard C, Breithardt Gunter, Berkowitz Scott D, Halperin Jonathan L, Hankey Graeme J, Hacke Werner, Maha..., Circulation, 1/16/2015
• Measurement tools and antidotes for non-vitamin K oral anticoagulants  
  Becker RC, J Thomb Thrombolysis, 1/14/2015
• Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomized clinical trial  
  Lincoff A Michael, Mehran Roxana, Povsic Thomas J, Zelenkofske Steven L, Huang Zhen, Armstrong Paul W, Steg P Gabriel, Bode Christoph, Cohen Mauricio G, Buller Christo..., Lancet, 1/4/2015
• Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated with Rivaroxaban or Warfarin ROCKET AF TRIAL  
  Sherwood Matthew W, Nessel Christopher, Hellkamp Anne, Mahaffey Kenneth, Piccini Jonathan, Shu Eun-Young, Becker Richard, Singer Daniel E, Halperin Jonathan L, Hankey ..., JACC, 1/1/2015
• Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation  
  Douketis JD, Spyrophoulos AC, Kaatz S, Becker RC, Caprini Jam Dunn AS, Garcia DA, Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AC, Hasselblad V, Ortel TL; BRIDGE..., N England J Med, 1/1/2015
• Are at least 12 months of dual antiplatelet therapy needed for all patients with drug-eluting stents? Not all patients with drug-eluting stents need at least 12 months...  
  Becker RC, Helmy T, Circulation, 1/1/2015
• Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial  
  Patel Manesh R, Becker, Richard C, Wojdyla Daniel M, Emanuelsson Hakan, Hiatt William R, Horrow Jay, Husted Steen, Mahaffey Kenneth W, Steg P Gabriel, Storey Robert F,..., EUR J Prev Cardiol, 1/1/2015
• The NLRC4 Inflammasome Is an Important Regulator of Interleukin-18 Levels in Patients with Acute Coronary Syndromes: A Genome-Wide Association Study in the PLATO Trial  
  Johansson A, Eriksson N, Becker RC, Storey RF, Himmelmann A, Hagstrom E, Varenhorst C, Axelsson T, Barratt BJ, James SK, Katus HA, Steg G, Syvanen AC, Wallentin L, Sie..., Circ Cardiovasc Genet, 1/1/2015
• Effect of genetic variations on ticagrelor plasma levels and clinical outcomes  
  Varenhorst Christoph, Erilsson Niclas, Johansson Asa, Barratt Bryan, Hagstrom Emil, Akerblom Axel, Syvanen Ann-Christine, Becker Richard C, James Stefan K, Katis Hugo ..., Eur Heart J, 1/1/2015
• Aspirin dosing in cardiovascular disease prevention and management: an update  
  Ganjehei L, Becker RC, J Thomb Thrombolysis, 1/1/2015
• Efficacy and safety of rivaroxaban in patients with diabetes and nonvascular atrial fibrillation: The Rivaroxaban Once-daily Oral, Direct Factor Xa Inhibition Compared...  
  Bansilal S, Bloomgarden Z, Halperin JL, Hellkamp AS, Lokhnygina Y, Patel MR, Becker RC, Breithardt G, Hacke W, Hankey GJ, Nessel CC, Singer DE, Berkowitz SD, Piccini J..., Am Heart J, 1/1/2015
• The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: Rationale and a summary of the available evidence from pha...  
  Krishnamoorthy A, Sherwood MW, Lopes RD, Becker RC, Am Heart J, 1/1/2015
• Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results from the ROCKET AF Trial  
  Singer DE, Hellkamp AS, Yuan Z, Lokhnygina Y, Patel MR, Piccini J, Hankey GJ, Vreithardt G, Halperin J, Becker RC, Hacke W, Nessel CC, Mahaffey KW, Fox KAA, Califf RM ..., J Am Heart Assoc, 1/1/2015
• total of 600 publication, 15 books, editorial boards and journal editor  
  richard c becker,MD, 20 top tier journals
• Cardiovascular events in acute coronary syndrome patients with peripheral aterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial  
  Patel MR, Becker RC, Wojdyla DM, Emanuelsson H, Hiatt WR, Horrow J, Husted S, Mahaffey KW, Steg PG, Storey RF, Wallentin L, James Sk, Eur J Prev Cardiol, 1/15/2014
• Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the Platelet Inhibition and Patient Outcomes (PLATO)Trial  
  Mahaffey KW, Held C, Wojdyla DM, James SK, Katus HA, Husted S, StegPG, Cannon CP, Becker RC, Storey RF, Khurmi NS, Nicolau JC, Yu C-M, Ardissino D, Budaj A, MoraisJ, M..., J Am Coll Cardiol, 1/1/2014
• Join now to see all

Books/Book Chapters

• Consultative Hemostasis and Thrombosis 
  Chapter: Hemostatic Aspects of Cardiovascular Medicine. 
  Page 342 - 394Vemulapalli, S., Becker, R.C.Editors: Craig S. Kitchens, Craig M. Kessler and Barbara S. Konkle.Elsevier SaundersEdition 3rd,2013
• Advances in Cardiology. 
  Chapter: Protease-Activated Receptor-1 Inhibitors: A novel Class of Antiplatelet Agents for the Treatment of Patients with Acute Coronary Syndrome. Antiplatelet Therapy in ACS and A-Fib. 
  Leonardi S, Tricoci P, Becker RCEditors: J.S. Borer.Karger2012
• Handbook of Experimental Pharmacology. 
  Chapter: Par-1 Inhibitors: A Novel Class of Antiplatelet Agents for the Treatment of Patients with Atherothrombtosis. 
  Leonardi S, Becker RCSpringer-Verlag, Berlin, Heidelberg2012
• Irwin and Rippe’s Procedures, Techniques and Minimally Invasive Monitoring in Intensive Care Medicine. 
  Chapter: Pericardiocentesis. 
  Smith CS, Becker RCEditors: Becker RC.Lippincott Williams and WilkinsEdition 5th,2012
• Genomic and Personalized Medicine, Two-Vol Set 
  Chapter: Hemostasis and Thrombosis. 
  Page 602 - 611Becker RC, Voora D, Shah SHEditors: Geoffrey S. Ginsburg and Huntington F. Willard.Academic Press, Oxford2012
• McGraw Hill Specialty Board Review, Cardiology. 
  Chapter: Critical Care for the Cardiologist. 
  Page 189 - 196Katz JN, Becker RCEditors: Ragavendra R. Baliga, M.D..2012
• Antithrombotic Therapy 
  Becker RC, Fintel DJ, Green DProfessional Communications Inc., New York, NYEdition 5th,2011
• Acute Coronary Syndromes. A Companion to Braunwalds Heart Disease. 
  Chapter: Antiplatelet Therapy. 
  Page 201 - 221Becker RC, Lohrman J and Gurbel PElsevier SaundersEdition 2nd,2010
• Antithrombotic Therapy in the Prevention of Ischemic Stroke. 
  Becker RC, Spencer FAOxford American Pocket notes. Oxford University Press2010
• Cardiac Biomarkers in Clinical Practice. 
  Chapter: Rationale for Measurement of Thrombosis Markers in Cardiology. 
  Page 631 - 661Patel MJ, Becker RCEditors: James L. Januzzi, Jr.Jones and Bartlett Publishers2010
• Cardiac Intensive Care 
  Chapter: Evolution of the Coronary Care Unit: Past, Present and Future. 
  Katz JN, Becker RCEditors: Allen Jeremias and David L. Brown.Saunders, ElsevierEdition 2nd,2010
• Genomic and Personalized Medicine, Volume 1 and 2. 
  Chapter: Hemostasis and Thrombosis 
  Becker RC, Andreotti FEditors: Huntington F. Willard an Geoffrey S. Ginsburg.Elsevier2009
• Thrombosis and Thrombolysis. 
  Chapter: Factor IXa Inhibitors. New Therapeutic Agents 
  Becker RC, Chan Mark, Howard EL, Becker KCD, Rusconi CPEditors: Jane E. Freedman and Joseph Loscalzo.Inform HealthcareEdition 3rd,2009
• Manual of Intensive Care Medicine. 
  Chapter: Pericardiocentesis: Procedures, Techniques and Minimally Invasive Monitoring 
  Page 80 - 85Becker RCEditors: Irwin RS, J Rippe.Lippincott Williams and Wilkins, Philadelphia, PAEdition 4th,2008
• Irwin and Rippe’s Intensive Care Medicine. 
  Chapter: Antithrombotic Therapy. 
  Page 1360 - 1375Becker RCEditors: Irwin RS, Rippe JM.Lippincott Williams and WilkinsEdition 6th,2008
• Irwin and Rippe’s Intensive Care Medicine. 
  Chapter: Pericardiocentesis. 
  Page 80 - 85Becker RC. In Irwin RS, Rippe JMEditors: Irwin RS, Rippe JM.Lippincott Williams and WilkinsEdition 6th,2008
• Dx/Rx: Coronary Thrombosis 
  Becker RC, Spencer FAJones and Bartlett PublishersEdition 2nd,2007
• Hemostatic Aspects of Cardiovascular Medicine. 
  Chapter: Consultative Hemostasis and Thrombosis. 
  Page 339 - 369Becker RC, Berkowitz S. In Kitchens CS, Alving BM, Kesler CMSaunders ElsevierEdition 2nd,2007
• Fibrinolytic and Antithrombotic Therapy: Theory, Practice, and Management. 
  Becker RCOxford University Press2006
• Contemporary Cardiology Cardiovascular Biomarkers: Pathophysiology and Disease Management. 
  Chapter: Clinical and Research Applications of Markers and Thrombosis. 
  Page 451 - 466Patel MR, Becker RCHumana Press Inc.2006
• Textbook of Cardiovascular Medicine: Section Eight, Vascular Biology and Medicine. 
  Chapter: Venous Thromboembolism. 
  Page 1569 - 1584Tapson VE, Becker RCLippincott Williams and Wilkins2006
• Manual of Intensive Care Medicine 
  Chapter: Critical Care of Pericardial Disease. 
  Page 152 - 160Becker RCEdition 4th,2006
• Critical Pathways in Cardiovascular Medicine. 
  Chapter: Approach to the Patient with Complicated Myocardial Infarction. 
  Page 129 - 154Becker RCLippincott Williams Wilkins2006
• Antithrombotic Therapy 
  Becker RC, Fintel DJ, Green DProfessional Communications Inc., New York, NYEdition 4th,2006
• Dx/Rx: Coronary Thrombosis 
  Becker RC, Spencer FAJones and Bartlett PublishersEdition 1st,2005
• Join now to see all

Abstracts/Posters

• Factors Associated With Major Bleeding Events.
  Goodman SG, Wojdyla DM, Piccini JP, White, HD, Paolini JF, Nessel CC, Berkowitz SD, Mahaffey KW, Patel MR, Sherwood MW, Becker, RC, Halperin JL, Hacke W, Singer DE, Ha..., JACC, 1/11/2014
• The Use Of Dual Antiplatlet Therapy And Patient Outcomes In Those Undergoing PCI In The Rocket AF Trial.
  Sherwood MW, Jones S, Cyr D, Becker R, Berkowitz S, Washam J, Breithardt G, Fox K, Halperin J, Hankey G, Singer D, Piccini J, Nessel C, Mahaffey K, Califf R, Hacke W, ..., JACC, 1/1/2014
• Use And Outcomes Of Antiarrhythmic Therapy In Patients With Atrial Fibrillation Receiving Oral Anticoagulation: Results From The Rocket AF Trial.
  Steinberg B, Hellkamp A, Lokhnygina Y, Halperin J, Breithardt G, Passman R, Hankey G, Patel M, Becker R, Singer D, Berkowitz S, Nessel C, Mahaffey K, Fox K, Califf R, ..., JACC, 1/1/2014
• Ticagrelor Plasma Levels But Not Clinical Outcomes Are Associated With Transporter And Metabolism Enzyme Genetic Polymorphisms.
  Varenhorst C, Eriksson N, Johansson A, Barratt B, Akerblom A, Hagstrom E, Syvanen A-C, Becker R, James S, Katus H, Husted S, Steg G, Siegbahn A, Voora D, Storey R, Wal..., JACC, 1/1/2014
• Role of Admission Cardiac Biomarkers In Risk Stratification Of Patients With ST-Elevation Myocardial Infarction: Insights From The Platelet Inhibition And Patient Outc...
  Velders M, Wallentin L, Becker R, van Boven AJ, Himmelmann A, Husted S, Lindholm D, Morais J, Siegbahn A, Storey R, Wernroth L, James S, JACC, 1/1/2014
• Genetic Polymorphisms and Relationship to Cystatin C Concentrations and Outcome – Results From the Platelet Inhibition and Patient Outcomes Study.
  Akerblom A, Wallentin L, Siegbahn A, Becker RC, Budaj A, Himmelmann A, Husted S, Storey RF, Eriksson N, Johansson a, James SK, Circulation, 1/1/2013
• Are There Any Causal Relations Between Growth Differentiation Factor 15 and Outcomes in Patients With Acute Coronary syndrome? – A Report From the Plato Gwas Study.
  Hagstrom E, Eriksson N, Johansson a, Bertilsson M, Axelsson T, Barratt BJ, Becker RC, Himmelmann A, James SK, Katus HA, Siegbahn A, Steg PG, Storey RF, Syvanen A, Vare..., Circulation, 1/1/2013
• Management of Major Bleeding Events in Patients Treated With Rivaroxaban Versus Warfarin: Results From the ROCKET AF Trial
  Kang HJ, Clare RM, Gao R, Himmelmann A, Held C, Wallentin L, James S, Becker RC, Circulation, 1/1/2013
• Response to Letter Regarding Article, “Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of...
  Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR, Mahaffey KW, Halperin J, Breihardt G, Hankey GJ, Hacke W, Becker RC, Nessel CC, Fox KAA, Cal..., Circulation, 1/1/2013
• Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R2CHADS2 Index in the ROCKET AF (R...
  Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR, Mahaffey KW, Halperin JL, Breithardt G, Hankey GJ, Hacke W, Becker RC, Nessel CC, Fox KAA, C..., Circulation, 1/1/2013
• Sex Differences in Platelet Reactivity, Cardiovascular and Psychological Response to Mental Stress in Patients with Known Coronary Artery Disease: Data From the Respon...
  Samad Z, Boyle S, Vora AN, Becker RC, Ortel TL, Kuhn C, Williams RB, Rogers JG, O’Connor C, Velazquez EJ, Jiang W, Circulation, 1/1/2013
• Evaluation of the Effect of Interleukin 18 Associated Genetic Polymorphisms on Risk of Cardiovascular Events in Patients With Acute Coronary Syndrome.
  Siegbahn A, Johansson a, Eriksson N, Hagstrom E, Varenhorst C, akerblom A, Bertilsson M, Axelsson T, Barratt BJ, Becker RC, Himmelmann A, James SK, Katus HA, Steg PG, ..., Circulation, 1/1/2013
• Biomarkers in Relation to the Effects of Ticagrelor Compared with Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed with or without In-Hospital ...
  Wallentin L, Lindholm D, Siegbahn A, Wernroth L, Becker RC, Cannon CP, Cornel JH, Himmelmann L, Giannitsis E, Harrington RA, Held C, Husted S, Katus HA, Mahaffey KW, S..., Circulation, 1/1/2013
• Association Between Platelet Aggregation and Mental Stress Induced Myocardial Ischemia: Results from the REMIT Trial.
  Harrison RW, Becker R, Ortel T, Kuchibhatla M, Boyle S, Samad Z, Velazquez EJ, Wilson J, Kuhn C, Williams R, O’Connor C, Jiang W, J Am Coll Cardiol, 1/1/2013
• Mental Stress Induced Myocardial Ischemia May Be More Common Than Exercise-Induced Ischemia.
  Jiang W, Samad Z, Boyle S, Becker RC, Williams R, Kuhn C, Ortel TL, Rogers J, Kuchibhatla M, O’Connor C, Velazquez EJ, J Am Coll Cardiol, 1/1/2013
• Antithrombotic Treatment in Transcatheter Aortic Valve Implantation.
  Rodes-Cabau J, Dauerman HL, Cohen MG, Mehran R, Small EM, Smyth SS, Costa MA, Mega JL, O’Donoghue ML, Ohman EM, Becker, RC, JACC, 1/1/2013
• Rivaroxaban Compared with Warfarin in Patients with Atrial Fibrillation and Diabetes: A Subgroup Analysis of the ROCKET AF Trial.
  Halperin JL, Bloomgarden Z, Hellkamp A, Lokhnygina A, Patel M, Becker RC, Breithardt G, Hacke W, Hankey G, Nessel C, Singer D, Berkowitz S, Califf R, Fox K, Mahaffey K, Circulation, 1/1/2012
• Efficacy and Safety of Rivaroxaban Compared with Warfarin Among Elderly Patients with Nonvalvular Atrial Fibrillation in the ROCKET-AF Trial.
  Halperin JL, Wojdyla D, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA, Stroke, 1/1/2012
• Predictors of Intracranial Hemorrhage Among Anticoagulated Patients with Atrial Fibrillation: Insights from the Rivaroxaban Once-daily oral Direct Factor Xa Inhibition...
  Hankey GJ, Stevens S, Piccini JP, Lokhnygina Y, Mahaffey KW, Halperin JL, Patel MR, Breithardt G, Singer DE, Becker RC, Paolini JF, Nessel CC, Hacke W, Fox KA, Califf RM, Stroke, 1/1/2012
• Renal dysfunction is a potent predictor of stroke and systemic embolism among individuals with atrial fibrillation: results from the ROCKET AF trial.
  Piccini JP, Stevens SR, Patel MR, Mahaffey KW, Paolini JF, Nessel CC, Becker RC, Halperin JL, Hacke W, Singer DE, Hankey GJ, Breithardt G, Fox KA, Califf RM, American Heart Association Scientific Sessions, Orlando, FL, 1/12/2011
• Predictors of Major Bleeding Risk: Insights from the Rivaroxaban Once-daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Strok...
  Goodman SC, Wojdyla DM, White HD, Piccini JP, Paolini JF, Nessel CC, Mahaffey KW, Patel MR, Becker RC, Halperin JL, Hacke W, Singer DE, Hankey GJ, Breithardt G, Fox K..., AHA Scientific Sessions, 1/12/2011
• Ischemic Cardiac Outcomes in Patients with AF Treated with vitamin K Antagonism or Factor Xa Inhibition: Results from the ROCKET AF Trial.
  Mahaffey KW, White HD, Nessel CC, Goodman SG, Piccini JP, Patel MR, Paolini JF, Becker RC, Halperin JL, Hacke W, Singer DE, Hankey GJ, Califf RM,Fox KAA, Breithardt G, AHA Scientific Sessions, 1/12/2011
• Individual Regional Determinants of Time in Therapeutic Range Among Patients Randomized to Warfarin in the ROCKET AF Trial of Rivaroxaban.
  Singer DE, Hellkamp AS, Halperin JL, Mahaffey KW, Becker RC, Breithardt G, Hankey GJ, Hacke W, Patel MR, Califf RM, Fox KAA, AHA Scientific Sessions, 1/12/2011
• Cystatin C is an independent risk predictor for death or myocardial infarction in patients with ST-elevation as well as in non-ST-elevation Acute Coronary Syndrome – R...
  Åkerblom A, Wallentin L, Siegbahn A, Becker RC, Budaj, A, Buck, K, Horrow J, Husted S, Katus H, Olofsson S, Gabriel P, Storey RF, Åsenblad N, and James SK, for the ..., ACC Scientific Sessions, 1/1/2011
• Effect of Apixaban, an Oral, Direct and Selective Factor Xa Inhibitor on Inflammatory Biomarkers Following Acute Coronary Syndrome.
  Becker RC, Lin A, Yang HQ, Barret Y, Mohan P, Wang J, Wallentin L, Alexander J, ACC Scientific Sessions, 1/1/2011
• Join now to see all

Lectures

• Current Management of Myocardial Infarction 
  1/1/1999

Other

• CD Rom Educational Service. 
  Becker RC, Up-To-Date
  1/1/2016
• On behalf of The Executive Steering Committee and the ROCKET AF Study Investigators Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF TRIAL. 
  Wong KSL, Hu DY, Oomman A, Tan R-S, Patel MR, Singer DE, Breithardt G, Mahaffey KW, Becker RC, Califf R, Fox KAA, Berkowitz SD, Hacke W, Hankey GJ, Stroke Online
  http://stroke.ahajournals.org/content/early/2014/04/23/STROKEAHA.113.002968
  1/1/2014
• Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease 
  Becker RC
  http://www.uptodate.com/contents/early-trials-of-platelet-glycoprotein-iib-iiia-receptor-inhibitors-
  UpToDate, Wolters Kluwer Health - 2012-07-02
• Coronary artery patency and outcome after myocardial infarction 
  Becker RC, Kimmelstiel C
  http://www.uptodate.com/contents/coronary-artery-patency-and-outcome-after-myocardial-infarction
  UpToDate, Wolters Kluwer Health - 2012-06-05
• Patient Self-Testing and Anticoagulation Clinics 
  Becker RC, CD-Rom
  1/1/2003
• Acute Coronary Syndromes 
  Becker RC, CD-Rom
  1/1/2002
• The New Cardiology Management Guide. 
  Becker RC, On-line Education Resource for Practicing Cardiologists
  1/1/1998
• Insertion Techniques and Keys for Diagnosis Using Pulmonary Artery Catheters. 
  Becker RC, Video Tape
  1/1/1995
• Coronary Artery Disease: Antithrombotic Therapy 2010. 
  Becker RC, American College of Chest Physicians, International Guidelines Center
• Achieving Quality Anticoagulation in Patients with non-Valvular Atrial Fibrillation. 
  Becker RC, Boehringer Ingelheim
• Acute Coronary Syndromes. 
  Becker RC, Spencer F, Jones and Bartlett Clinical Cards
• Deep Vein Thrombosis and Pulmonary Embolism. 
  Becker RC, Spencer F, Jones and Bartlett Clinical Cards
• Join now to see all